All In Biotech

NDA 209884 · Novartis

Mayzent

Siponimod · Oral · Sphingosine 1-phosphate Receptor Modulator

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 26, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

17

4 Phase 3, 2 recruiting

FAERS reports

8,919

4,480 serious, 207 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2026.

MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Mechanism: Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 1, 2022 Supplement 7 · Efficacy LetterLabel
  • Mar 26, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • MAYZENT · SIPONIMOD EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
  • MAYZENT · SIPONIMOD EQ 0.25MG BASE · TABLET, ORAL · Prescription · TE AB
  • MAYZENT · SIPONIMOD EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Siponimod" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,002
  • headache892
  • dizziness674
  • multiple sclerosis relapse548
  • gait disturbance539
  • fall519
  • multiple sclerosis489
  • nausea424
  • drug ineffective422
  • lymphocyte count decreased421
  • product dose omission issue396
  • urinary tract infection385

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20142
20162
20172
20187
2019906
20202,147
20211,975
20221,551
20231,266
2024507
2025351
2026202

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mayzent (Siponimod)

2024 spending

$75.8M

Beneficiaries

850

6,850 claims

Per beneficiary

$89,232

$313.35 per unit

View as table
YearSpending
2020$44,651,698
2021$64,271,201
2022$71,384,518
2023$79,550,294
2024$75,847,094

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.